Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 1:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 61 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Advanced Parkinson's Disease Clear all
Completed Phase 4 Interventional Results available

A Phase 4, Open-label Study to Assess the Feasibility and Efficacy on Motor and Non-motor Symptoms of Switching From Pramipexole or Ropinirole to Rotigotine Transdermal Patch in Subjects With Advanced Idiopathic Parkinson's Disease

NCT01711866
View directory record Official record
Conditions
Advanced Idiopathic Parkinson's Disease
Interventions
Rotigotine
Drug
Lead sponsor
UCB BIOSCIENCES GmbH
Industry
Eligibility
30 Years to 80 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Anniston, Alabama • Atlantis, Florida • Miami Springs, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2014 · Synced Jul 23, 2026, 1:27 AM EDT
Completed Phase 3 Interventional Results available

Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease

NCT04380142
View directory record Official record
Conditions
Parkinson's Disease (PD)
Interventions
ABBV-951, Placebo for Levodopa/Carbidopa (LD/CD), Levodopa/Carbidopa (LD/CD), Placebo for ABBV-951
Drug
Lead sponsor
AbbVie
Industry
Eligibility
30 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
70
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2022 · Synced Jul 23, 2026, 1:27 AM EDT
Recruiting No phase listed Observational

A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Pallidotomy for the Treatment of Advanced, Idiopathic Parkinson's Disease With Medication-refractory Moderate to Severe Motor Complications

NCT05539196
View directory record Official record
Conditions
Movement Disorders, Neurology, Parkinsons Disease
Interventions
Exablate Pallidotomy, Unilateral
Device
Lead sponsor
InSightec
Industry
Eligibility
30 Years to 99 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
4
States / cities
Baltimore, Maryland • New York, New York • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Jul 23, 2026, 1:27 AM EDT
Completed Phase 3 Interventional

SLV308 for Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations

NCT00406588
View directory record Official record
Conditions
Advanced Stage Parkinson's Disease
Interventions
Levodopa (Pardoprunox), Placebo Comparator
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
30 Years and older
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
15
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2015 · Synced Jul 23, 2026, 1:27 AM EDT
Terminated Phase 2 Interventional

Study of AAV-GAD Gene Transfer Into the Subthalamic Nucleus for Parkinson's Disease

NCT00643890
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Bilateral surgical infusion of AAV-GAD into the subthalamic nucleus
Genetic
Lead sponsor
Neurologix, Inc.
Industry
Eligibility
30 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
7
States / cities
Stanford, California • Aurora, Colorado • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2012 · Synced Jul 23, 2026, 1:27 AM EDT
Active, not recruiting Not applicable Interventional

RAD 1601: EDGE Radiosurgery for Intractable Essential Tremor and Tremor-Dominant Parkinson's Disease

NCT03305588
View directory record Official record
Conditions
Essential Tremor, Parkinson Disease
Interventions
Unframed Virtual Cone
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 99 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Jul 23, 2026, 1:27 AM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain

NCT01744496
View directory record Official record
Conditions
Advanced Idiopathic Parkinson's Disease
Interventions
Rotigotine, Placebo
Drug
Lead sponsor
UCB BIOSCIENCES GmbH
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
10
States / cities
Gilbert, Arizona • Sunnyvale, California • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Jul 23, 2026, 1:27 AM EDT
Terminated Phase 2 Interventional

Pilot Study of Safety and Efficacy of Spheramine

NCT00761436
View directory record Official record
Conditions
Parkinson''s Disease
Interventions
Spheramine (BAY86-5280)
Biological
Lead sponsor
Bayer
Industry
Eligibility
40 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 7, 2021 · Synced Jul 23, 2026, 1:27 AM EDT
Completed Phase 3 Interventional

Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease

NCT04750226
View directory record Official record
Conditions
Parkinson's Disease (PD)
Interventions
ABBV-951
Drug
Lead sponsor
AbbVie
Industry
Eligibility
30 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
47
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Jul 23, 2026, 1:27 AM EDT
Completed Phase 3 Interventional Results available

Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's Disease

NCT00335153
View directory record Official record
Conditions
Advanced Parkinson's Disease
Interventions
Levodopa-carbidopa intestinal gel, CADD-Legacy® 1400 ambulatory infusion pump, PEG tube, J-tube
Drug · Device
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
30 Years and older
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
31
States / cities
Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2015 · Synced Jul 23, 2026, 1:27 AM EDT
Recruiting Phase 1 Interventional

SAD Study in Patients With Parkinson's Disease and Motor Fluctuations

NCT07422675
View directory record Official record
Conditions
PARKINSON DISEASE (Disorder), Advanced Parkinson's Disease
Interventions
SER-252 (PEOZ-apomorphine), enFuse
Drug · Device
Lead sponsor
Serina Therapeutics
Industry
Eligibility
40 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
4
States / cities
Englewood, Colorado • Hallandale, Florida • Maitland, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jul 23, 2026, 1:27 AM EDT
Completed No phase listed Observational

Observational Study Evaluating Long-Term Effectiveness of Duodopa/Duopa in Patients With Advanced Parkinson's Disease

NCT02611713
View directory record Official record
Conditions
Advanced Parkinson's Disease
Interventions
Not listed
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
19
States / cities
Birmingham, Alabama • Boca Raton, Florida • Gainesville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Jul 23, 2026, 1:27 AM EDT
Completed No phase listed Observational

DiSCERN: Advanced PD Therapy Candidacy and Evaluation System

NCT05351580
View directory record Official record
Conditions
Parkinson Disease
Interventions
DiSCERN
Device
Lead sponsor
Great Lakes NeuroTechnologies Inc.
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Cincinnati, Ohio • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 25, 2025 · Synced Jul 23, 2026, 1:27 AM EDT
Completed Phase 1 Interventional

VY-AADC02 for Parkinson's Disease With Motor Fluctuations (RESTORE-1)

NCT03562494
View directory record Official record
Conditions
Parkinson's Disease
Interventions
VY-AADC02, Sham (Placebo) Surgery
Biological · Other
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
40 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
11
States / cities
Irvine, California • Sacramento, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Jul 23, 2026, 1:27 AM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects

NCT00357994
View directory record Official record
Conditions
Advanced Parkinson's Disease
Interventions
Levodopa carbidopa intestinal gel (LCIG), Placebo gel, Levodopa carbidopa (LC) oral encapsulated immediate release (IR) tablets, Placebo (PBO) oral capsules, CADD-Legacy® 1400 ambulatory infusion pump, PEG tube, J-tube
Drug · Device
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
30 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
8
States / cities
Los Angeles, California • Englewood, Colorado • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2015 · Synced Jul 23, 2026, 1:27 AM EDT
Completed Phase 2 Interventional

A Study to Assess the PK and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson's Disease

NCT02271503
View directory record Official record
Conditions
Parkinson's Disease
Interventions
CD-LD IR, IPX203 180 mg, IPX203 270 mg, Rytary 195 mg, Rytary 145 mg
Drug
Lead sponsor
Impax Laboratories, LLC
Industry
Eligibility
40 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
11
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Fountain Valley, California + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2019 · Synced Jul 23, 2026, 1:27 AM EDT
Completed Phase 3 Interventional Results available

A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066

NCT01130493
View directory record Official record
Conditions
Parkinson's Disease
Interventions
IPX066, CLE
Drug
Lead sponsor
Impax Laboratories, LLC
Industry
Eligibility
30 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
12
States / cities
Fresno, California • Sunnyvale, California • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2019 · Synced Jul 23, 2026, 1:27 AM EDT
Completed Phase 3 Interventional Results available

Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease

NCT00660673
View directory record Official record
Conditions
Advanced Parkinson's Disease
Interventions
Levodopa-Carbidopa Intestinal Gel (LCIG), CADD-Legacy® 1400 ambulatory infusion pump, Percutaneous Endoscopic Gastrostomy with jejunal extension tube (PEG-J)
Drug · Device
Lead sponsor
AbbVie
Industry
Eligibility
30 Years to 99 Years
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
31
States / cities
Birmingham, Alabama • Encinitas, California • Fountain Valley, California + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2022 · Synced Jul 23, 2026, 1:27 AM EDT
Completed Phase 1 Interventional

Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's Disease

NCT03065192
View directory record Official record
Conditions
Idiopathic Parkinson's Disease, Parkinson's Disease, Basal Ganglia Disease, Brain Diseases, Central Nervous System Diseases, Movement Disorders, Nervous System Diseases, Neurodegenerative Diseases, Parkinsonian Disorders
Interventions
VY-AADC01
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
40 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
4
States / cities
San Francisco, California • Atlanta, Georgia • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2022 · Synced Jul 23, 2026, 1:27 AM EDT
Completed Not applicable Interventional

ExAblate Transcranial MRgFUS of the Subthalamic Nucleus for Treatment of Parkinson's Disease

NCT02246374
View directory record Official record
Conditions
Parkinson's Disease
Interventions
ExAblate Transcranial System
Device
Lead sponsor
InSightec
Industry
Eligibility
30 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Jul 23, 2026, 1:27 AM EDT
Recruiting Phase 1Phase 2 Interventional

This Clinical Trial is Designed to Evaluate the Safety, Tolerability, Feasibility and Preliminary Efficacy of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in Patients With Parkinson's Disease.

NCT07102342
View directory record Official record
Conditions
Parkinson Disease
Interventions
Human Dopaminergic Progenitor Cells
Biological
Lead sponsor
iRegene Therapeutics Co., Ltd.
Industry
Eligibility
30 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Jul 23, 2026, 1:27 AM EDT
Completed Phase 3 Interventional Results available

Carbidopa-Levodopa (CD-LD) ER Alone or in Combination With CD-LD IR to IPX066 Followed by IPX066 Extension Safety Study

NCT01411137
View directory record Official record
Conditions
Parkinson's Disease
Interventions
IPX066
Drug
Lead sponsor
Impax Laboratories, LLC
Industry
Eligibility
30 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
8
States / cities
Birmingham, Alabama • La Jolla, California • Sunnyvale, California + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2019 · Synced Jul 23, 2026, 1:27 AM EDT
Completed Not applicable Interventional

Blood Flow Restriction and Exercise in Parkinson's Disease

NCT07221994
View directory record Official record
Conditions
Parkinson' Disease
Interventions
Blood flow restriction (BFR) and aerobic exercise via recumbent stepping (Nu-Step)
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jul 23, 2026, 1:27 AM EDT
Completed Phase 4 Interventional Results available

A Fixed Dose Study of Ropinirole Prolonged Release as Adjunctive Treatment in Patients With Advanced Parkinson's Disease

NCT01494532
View directory record Official record
Conditions
Parkinson Disease
Interventions
ropinirole/L-dopa, placebo/L-dopa
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years and older
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
9
States / cities
Fountain Valley, California • Pasadena, California • Reseda, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2018 · Synced Jul 23, 2026, 1:27 AM EDT